protein

TGF-beta 2/TGFB2

MBS8532994

0.01 mg

280 USD

Protein

TGF-beta 2/TGFB2

[TGF-beta 2/TGFB2]

[Transforming growth factor beta-2; TGFB2; Polyergin; G-TSF; Glioblastoma-derived T-cell suppressor factor; Cetermin; BSC-1 cell growth inhibitor; TGF-beta-2]

[transforming growth factor beta-2 isoform 2 preproprotein; Transforming growth factor beta-2; transforming growth factor beta-2; transforming growth factor beta 2; BSC-1 cell growth inhibitor; Cetermin; Glioblastoma-derived T-cell suppressor factor; G-TSF]

[TGFB2]

[TGFB2; TGFB2; LDS4; G-TSF; TGF-beta2; TGF-beta-2; G-TSF; LAP]

414

Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized from a 0.2 um filtered solution of 4 mM HCl.

Lyophilized protein should be stored at <-20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples are stable at <-20°C for 3 months.

Expression System: Human cells. Species: Human. Endotoxin: Less than 0.1 ng/ug (1 IEU/ug) as determined by LAL test.

Description: Recombinant Human Transforming Growth Factor beta 2 is produced by our Mammalian expression system and the target gene encoding Ala303-Ser414 is expressed. Background: Transforming growth factor beta-2 (TGF-beta2) is a secreted protein which belongs to the TGF-beta family. It is known as a cytokine that performs many cellular functions and has a vital role during embryonic development. The precursor is cleaved into mature TGF-beta-2 and LAP, which remains non-covalently linked to mature TGF-beta-2 rendering it inactive. It is an extracellular glycosylated protein. It is known to suppress the effects of interleukin dependent T-cell tumors. Defects in TGFB2 may be a cause of non-syndromic aortic disease (NSAD).

4507463

NP_003229.1

NM_003238.4

P61812

AGE-RAGE Signaling Pathway In Diabetic Complications (1319988); AGE-RAGE Signaling Pathway In Diabetic Complications (1319775); ATF-2 Transcription Factor Network Pathway (138006); Amoebiasis Pathway (167324); Amoebiasis Pathway (167191); Cell Cycle Pathway (83054); Cell Cycle Pathway (463); Chagas Disease (American Trypanosomiasis) Pathway (147809); Chagas Disease (American Trypanosomiasis) Pathway (147795); Chronic Myeloid Leukemia Pathway (83116)

This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate a latency-associated peptide (LAP) and a mature peptide, and is found in either a latent form composed of a mature peptide homodimer, a LAP homodimer, and a latent TGF-beta binding protein, or in an active form consisting solely of the mature peptide homodimer. The mature peptide may also form heterodimers with other TGF-beta family members. Disruption of the TGF-beta/SMAD pathway has been implicated in a variety of human cancers. A chromosomal translocation that includes this gene is associated with Peters' anomaly, a congenital defect of the anterior chamber of the eye. Mutations in this gene may be associated with Loeys-Dietz syndrome. This gene encodes multiple isoforms that may undergo similar proteolytic processing. [provided by RefSeq, Aug 2016]

TGF-beta 2 has suppressive effects on interleukin-2 dependent T-cell growth.

0.01 mg

280 USD